Rely T25 A-side Rely OEM A-side

Hazard statements (CLP)

H317, H330, H334, H350, H361d, H373, H400, H410

Code

Statements

H317

May cause an allergic skin reaction

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification

2.2 Label elements

Labelling

Hazard pictograms

GHS06 GHS08 GHS09

Signal word

Danger

Contains

Residues (petroleum), catalytic reformer fractionator; m-tolylidene diisocyanate

Hazard statements

H317 - May cause an allergic skin reaction. H330 - Fatal if inhaled. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. H350 - May cause cancer. H361d - Suspected of damaging the unborn child. H373 - May cause damage to organs through prolonged or repeated exposure. H410 - Very toxic to aquatic life with long lasting effects.

Precautionary statements

P201 - Obtain special instructions before use. P260 - Do not breathe vapours. P273 - Avoid release to the environment. P280 - Wear protective gloves, protective clothing, eye protection, face protection. P304+P340 - IF INHALED: Remove person to fresh air and keep comfortable for breathing. P308+P313 - IF exposed or concerned: Get medical advice, medical attention. P310 - Immediately call a POISON CENTER/doctor. P342+P311 - If experiencing respiratory symptoms: Call a POISON CENTER, doctor. P391 - Collect spillage. P403+P233 - Store in a well-ventilated place. Keep container tightly closed. P501 - Dispose of contents and container to an approved waste disposal plant.

Additional information

Restricted to professional users. As from 24 August 2023 adequate training is required before industrial or professional use.

Results of PBT and vPvB assessment

Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII. Persons suffering from asthma or eczema and persons who have chronic lung diseases, skin or respiratory allergies to isocyanates should not work with the material. The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %